MedTrace Logo

Vaccine Immunity and Inflammation in the Aging Person Living With HIV

NCT06514547 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-06-12

No results posted yet for this study

Summary

This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.

Conditions

  • HIV Infections
  • Age

Interventions

BIOLOGICAL

Conjugate Pneumococcal Vaccine 20 (PCV20)

Vaccine

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Hennepin Healthcare Research Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-08
Primary Completion
2028-09-15
Completion
2029-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06514547 on ClinicalTrials.gov